Ribociclibiä

Ribociclib is a medication used in the treatment of breast cancer. It is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), enzymes involved in the progression of the cell cycle. The medication is constructed to bind to the ATP-binding pocket of CDK4/6, preventing the phosphorylation of Retinoblastoma protein and subsequently preventing cell proliferation. Ribociclib is used in combination with an aromatase inhibitor or fulvestrant in postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer.

Ribociclib was approved by the United States Food and Drug Administration (FDA) on March 23, 2018 for the treatment of hormone receptor-positive, HER2-negative breast cancer in postmenopausal women. It is also approved in the European Union for the treatment of this condition, as well as in Japan and several other countries. The medication is administered orally once daily, as part of a combination regimen with an aromatase inhibitor or fulvestrant. Common side effects of ribociclib include neutropenia, leukopenia, anemia, thrombocytopenia, nausea, and fatigue.

Research has shown that ribociclib has a significant effect on the progression-free survival rate of patients with hormone receptor-positive breast cancer. Clinical trials have demonstrated an increase in progression-free survival of up to 16 months in patients treated with ribociclib in combination with an aromatase inhibitor compared to those treated with an aromatase inhibitor alone. The medication has also demonstrated efficacy in combination with fulvestrant. Overall, ribociclib has shown promise as a treatment for hormone receptor-positive breast cancer and has become a valuable option for healthcare providers and patients.